[go: up one dir, main page]

NO20081074L - Macrocyclisk inhibitorer av hepatitis C-virus - Google Patents

Macrocyclisk inhibitorer av hepatitis C-virus

Info

Publication number
NO20081074L
NO20081074L NO20081074A NO20081074A NO20081074L NO 20081074 L NO20081074 L NO 20081074L NO 20081074 A NO20081074 A NO 20081074A NO 20081074 A NO20081074 A NO 20081074A NO 20081074 L NO20081074 L NO 20081074L
Authority
NO
Norway
Prior art keywords
hepatitis
virus
inhibitors
macrocyclic inhibitors
hcv
Prior art date
Application number
NO20081074A
Other languages
English (en)
Inventor
Herman Augustinus De Kock
Kenneth Alan Simmen
Pierre Jean-Marie Bernard Raboisson
Karl Magnus Nilsson
Bengt Bertil Samuelsson
Asa Annicka Kristin Rosenquist
Mats Stefan Lindstrom
Pia Cecilia Kahnberg
Dmitry Antonov
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of NO20081074L publication Critical patent/NO20081074L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Inhibitorer av HCV med formel (I) og N-oksidene, saltene, og stereoisomerene derav, hvori den stiplede linjen representerer en eventuell dobbelbinding mellom atomene C7 og C8; R1 er hydrogen eller C1-6alkyl; R2 er hydrogen eller C1-6alkyl; og n er 3, 4, 5, eller 6; farmasøytiske sammensetninger som inneholder forbindelser (I) og fremgangsmåter for fremstilling av forbindelser (I) er tilveiebrakt. Biotilgjengelige kombinasjoner av inhibitorene av HCV med formel (I) med ritonavir er også tilveiebrakt.
NO20081074A 2005-07-29 2008-02-29 Macrocyclisk inhibitorer av hepatitis C-virus NO20081074L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05107066 2005-07-29
EP06101278 2006-02-03
PCT/EP2006/064812 WO2007014918A1 (en) 2005-07-29 2006-07-28 Macrocyclic inhibitors of hepatitis c virus

Publications (1)

Publication Number Publication Date
NO20081074L true NO20081074L (no) 2008-04-29

Family

ID=37102945

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081074A NO20081074L (no) 2005-07-29 2008-02-29 Macrocyclisk inhibitorer av hepatitis C-virus

Country Status (31)

Country Link
US (1) US8008251B2 (no)
EP (1) EP1913014B1 (no)
JP (1) JP5508713B2 (no)
KR (1) KR101321392B1 (no)
CN (1) CN101233147B (no)
AR (1) AR054881A1 (no)
AT (1) ATE496934T1 (no)
AU (1) AU2006274857B2 (no)
BR (1) BRPI0614515A2 (no)
CA (1) CA2616954C (no)
CY (1) CY1112001T1 (no)
DE (1) DE602006019879D1 (no)
DK (1) DK1913014T3 (no)
EA (1) EA200800485A1 (no)
GT (1) GT200600340A (no)
HR (1) HRP20110289T1 (no)
IL (1) IL188281A (no)
ME (1) ME01233B (no)
MX (1) MX2008001394A (no)
MY (1) MY139987A (no)
NO (1) NO20081074L (no)
NZ (1) NZ564542A (no)
PE (1) PE20070210A1 (no)
PL (1) PL1913014T3 (no)
PT (1) PT1913014E (no)
RS (1) RS51776B (no)
SG (1) SG163610A1 (no)
SI (1) SI1913014T1 (no)
TW (1) TWI437993B (no)
UY (1) UY29702A1 (no)
WO (1) WO2007014918A1 (no)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
SI1713823T1 (sl) 2004-01-30 2010-04-30 Medivir Ab Inhibitorji HCV NS-3 serin proteaze
US20090074815A1 (en) * 2005-04-22 2009-03-19 Sciclone Pharmaceuticals, Inc. Immunomodulator Compounds as Vaccine Enhancers
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7935670B2 (en) 2006-07-11 2011-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2097402B1 (en) * 2006-11-17 2014-04-09 Janssen R&D Ireland Macrocyclic inhibitors of hepatitis c virus
US8383583B2 (en) 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
RU2490272C2 (ru) 2008-02-04 2013-08-20 Айденикс Фармасьютикалз, Инк. Макроциклические ингибиторы серинпротеазы
CA2719008A1 (en) 2008-03-20 2009-09-24 Enanta Pharmaceuticals, Inc. Fluorinated macrocyclic compounds as hepatitis c virus inhibitors
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5529120B2 (ja) 2008-05-29 2014-06-25 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルス阻害剤
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2758072A1 (en) 2009-04-08 2010-10-14 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
CA2769652A1 (en) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9207002B2 (en) 2011-10-12 2015-12-08 International Business Machines Corporation Contaminant separator for a vapor-compression refrigeration apparatus
WO2014062196A1 (en) 2012-10-19 2014-04-24 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
JP6342922B2 (ja) 2013-03-07 2018-06-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
CN117186000A (zh) * 2023-08-16 2023-12-08 上海凌凯医药科技有限公司 一种喹啉类化合物的制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2135890C (en) 1992-12-29 1996-08-27 Dale J. Kempf Retroviral protease inhibitor (2s,3s,5s)-5-(n-(n-((n-methyl-n-((2-isopropyl-4- thiazolyl)methyl)amino)carbonyl)valinyl)amino)- 2-(n-((5-thiazolyl)methoxycarbonyl)amino)-1, 6-diphenyl-3-hydroxyhexane
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
CA2252465C (en) 1996-04-23 2007-07-03 Vertex Pharmaceuticals Incorporated Urea derivatives as inhibitors of impdh enzyme
JP4080541B2 (ja) 1996-10-18 2008-04-23 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ、特にｃ型肝炎ウイルスｎｓ３プロテアーゼの阻害因子
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
DE69816280T2 (de) 1997-03-14 2004-05-27 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren des impdh-enzyms
JP4452401B2 (ja) 1997-08-11 2010-04-21 ベーリンガー インゲルハイム （カナダ） リミテッド Ｃ型肝炎ウイルス阻害ペプチドアナログ
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
OA11848A (en) 1999-03-19 2006-03-08 Vertex Pharma Inhibitors of IMPDH enzyme.
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US6867185B2 (en) * 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
PL373399A1 (en) 2002-04-11 2005-08-22 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US20050075279A1 (en) * 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
ATE422895T1 (de) * 2003-04-16 2009-03-15 Bristol Myers Squibb Co Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus
US7125845B2 (en) * 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
ATE500264T1 (de) * 2003-09-22 2011-03-15 Boehringer Ingelheim Int Makrozyklische peptide mit wirkung gegen das hepatitis-c-virus
SI1713823T1 (sl) * 2004-01-30 2010-04-30 Medivir Ab Inhibitorji HCV NS-3 serin proteaze
PE20070211A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
WO2007014920A1 (en) * 2005-07-29 2007-02-08 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis c virus
JP2009502845A (ja) * 2005-07-29 2009-01-29 メディヴィル・アクチボラグ Ｃ型肝炎ウイルスの大環状インヒビター
ES2456617T3 (es) * 2005-07-29 2014-04-23 Janssen R&D Ireland Inhibidores macrocíclicos del virus de la hepatitis C

Also Published As

Publication number Publication date
NZ564542A (en) 2010-03-26
GT200600340A (es) 2007-02-26
CN101233147B (zh) 2012-06-20
EA200800485A1 (ru) 2009-04-28
PL1913014T3 (pl) 2011-06-30
AU2006274857B2 (en) 2012-11-29
CA2616954A1 (en) 2007-02-08
HRP20110289T1 (hr) 2011-05-31
IL188281A0 (en) 2008-04-13
AR054881A1 (es) 2007-07-25
EP1913014B1 (en) 2011-01-26
SI1913014T1 (sl) 2011-06-30
BRPI0614515A2 (pt) 2011-03-29
TWI437993B (zh) 2014-05-21
RS51776B (sr) 2011-12-31
CY1112001T1 (el) 2015-11-04
EP1913014A1 (en) 2008-04-23
ATE496934T1 (de) 2011-02-15
TW200801044A (en) 2008-01-01
AU2006274857A1 (en) 2007-02-08
JP2009502881A (ja) 2009-01-29
JP5508713B2 (ja) 2014-06-04
KR20080039430A (ko) 2008-05-07
US20080200503A1 (en) 2008-08-21
PT1913014E (pt) 2011-04-20
UY29702A1 (es) 2007-05-31
CN101233147A (zh) 2008-07-30
PE20070210A1 (es) 2007-04-16
IL188281A (en) 2015-01-29
US8008251B2 (en) 2011-08-30
DK1913014T3 (da) 2011-08-01
MX2008001394A (es) 2008-04-08
SG163610A1 (en) 2010-08-30
CA2616954C (en) 2013-12-24
MY139987A (en) 2009-11-30
WO2007014918A1 (en) 2007-02-08
KR101321392B1 (ko) 2013-10-30
DE602006019879D1 (de) 2011-03-10
HK1116503A1 (en) 2008-12-24
ME01233B (me) 2013-06-20

Similar Documents

Publication Publication Date Title
NO20081074L (no) Macrocyclisk inhibitorer av hepatitis C-virus
NO20081073L (no) Makrocykliske inhibitorer av hepatitt C virus
EA200970493A1 (ru) Макроциклические ингибиторы вируса гепатита с
TW200745118A (en) Macrocylic inhibitors of hepatitis C virus
TW200740775A (en) Macrocylic inhibitors of hepatitis C virus
PE20090630A1 (es) Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion
MXPA03005822A (es) Compuestos heterociclicos que tienen actividad antibacteriana, proceso para su preparacion y composiciones farmaceuticas que los contienen.
AP1753A (en) Thiophene derivatives as antiviral agents for flavvivirus infection
TW200800949A (en) Macrocylic inhibitors of hepatitis C virus
NO20080879L (no) HCV-NS3-proteaseinhibitorer
NO20082496L (no) Pyrazinderivater
NO20071642L (no) N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger
DK1392714T3 (da) Steroider som agonister for FXR
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20091409L (no) Pyridin-3-yl-derivater som immunmodulerende midler
TNSN07252A1 (en) Indole derivatives for treating viral infections
DE50005437D1 (en) Substituierte thien-3-yl-sulfonylamino(thio)carbonyl-triazolin(thi)one
NO20053794L (no) N-(1-benzyl-2-oxo-2-(1-piperazinyl) etyl)-1-piperidinkarboksamid-derivater og relaterte forbindelsers bruk som CGRP-antagonister for behandling av hodepine.
WO2005003087A3 (en) Oxazole derivatives as antibacterial agents
ATE505462T1 (de) Neue biologischaktive molekü le
AU8811401A (en) Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient
NO20074346L (no) Nye heterocykliske oksimforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
DK1156058T3 (da) Fremgangsmåde til fremstilling af (E,Z) 3-(2-aminoethoxyimino)-androstan-6,17-dion og analoger deraf
WO2003093247A3 (en) Antibacterial agents
NO20063111L (no) Fremgangsmate for fremstilling av tiazolpyrimidiner

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application